Posted by Michael Wonder on 20 May 2026
BioSyent announces Health Canada approval of Thyconvi (levothyroxine oral solution)
19 May 2026 - BioSyent announces that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone suppression.
BioSyent Pharma, a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi in Canada.
